Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy and Safety Study of KX2-391 Ointment 1% in Adult Subjects With Actinic Keratosis on the Face or Scalp

Trial Profile

A Phase 3, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy and Safety Study of KX2-391 Ointment 1% in Adult Subjects With Actinic Keratosis on the Face or Scalp

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tirbanibulin (Primary)
  • Indications Actinic keratosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Almirall S.A.; Athenex
  • Most Recent Events

    • 01 Jan 2024 Results of post hoc analysis (NCT03285477 ,N = 351 and NCT03285490 N = 351) assessing Efficacy and safety of tirbanibulin 1% ointment in actinic keratoses published in the Journal of the European Academy of Dermatology and Venereology
    • 21 Mar 2023 Results of post hoc analysis pooled from two Phase III studies (NCT03285477/NCT03285490)assessing hypo/hyperpigmentation changes and cosmetic outcomes were assessed by Fitzpatrick skin type in AK patients treated with tirbanibulin presented at the American Academy of Dermatology annual Meeting 2023
    • 19 Jul 2021 According to an Athenex media release, Almirall has received approval from the European Commission to market Klisyri (tirbanibulin), indicated for the topical treatment of actinic keratosis (AK) of the face or scalp in adults.This approval is based on the positive results from two pivotal Phase III studies (KX01-AK-003 and KX01-AK-004).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top